As we saw in the BRUIN CLL-322 trial, patients who are progressing on a covalent BTK inhibitor have pretty aggressive CLL at that point. So I think all of these patients, if they’re interested and potentially eligible for a clinical trial, should be referred for consideration of a trial. It’s not that a trial would be right for every patient, but I do think that many patients could benefit, and we still need to learn more about how best to treat these patients...
As we saw in the BRUIN CLL-322 trial, patients who are progressing on a covalent BTK inhibitor have pretty aggressive CLL at that point. So I think all of these patients, if they’re interested and potentially eligible for a clinical trial, should be referred for consideration of a trial. It’s not that a trial would be right for every patient, but I do think that many patients could benefit, and we still need to learn more about how best to treat these patients. A good example is the Phase III trials that are ongoing, directly comparing pirtobrutinib to BTK degraders. For a patient progressing on a frontline covalent BTK inhibitor, I think a trial like that is a great option, because if they’re randomized to pirtobrutinib, that’s probably what they would be getting anyway. If they’re randomized to a BTK degrader, we think these are very promising drugs and maybe better than pirtobrutinib in that context, but we don’t know yet, and that’s why the trials are ongoing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.